SCHEDULE OF RECONCILIATION OF ADJUSTED EBITDA (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Segment Reporting [Abstract] | ||||
| (Loss) income from continuing operations (GAAP Basis) | $ (1,501) | $ 1,011 | $ (404) | $ 2,232 |
| Depreciation and amortization | 141 | 111 | 386 | 307 |
| Stock-based compensation | 3,993 | 7 | 4,001 | 31 |
| Non-recurring legal expenses | 234 | 614 | ||
| Severance & related expense | 692 | |||
| Asset impairment - lab supplies | 198 | |||
| Loss on sale of asset | 104 | 104 | ||
| Lab supplies write-off | 217 | |||
| Taxes (benefit) expense | (884) | (11) | (517) | 7 |
| Note payable interest | 30 | 156 | ||
| Other income/expense, net | (15) | 10 | (33) | 25 |
| Change in fair value of note payable | 105 | 87 | ||
| Adjusted EBITDA | $ 2,072 | $ 1,263 | $ 4,368 | $ 3,735 |
| X | ||||||||||
- Definition Adjusted EBITDA From continuing operations. No definition available.
|
| X | ||||||||||
- Definition Asset impairment lab supplies. No definition available.
|
| X | ||||||||||
- Definition Fair value adjustment of note payable. No definition available.
|
| X | ||||||||||
- Definition Lab supplies writeoff. No definition available.
|
| X | ||||||||||
- Definition Severance & related expense. No definition available.
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for employee benefit and equity-based compensation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense for debt. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|